Robert M. Rifkin, MD, FACP, discusses how real-world studies on teclistamab and talquetamab presented at ASH 2024 reinforce their efficacy and impact on patient outcomes in relapsed/refractory multiple myeloma, while panelists discuss how clinicians should prioritize factors such as patient characteristics and treatment history when selecting the most appropriate bispecific therapy for these patients.
